These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
698 related articles for article (PubMed ID: 8306334)
1. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo. O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334 [TBL] [Abstract][Full Text] [Related]
2. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598 [TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152). Fujimoto K; Oka T; Morimoto M Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218 [TBL] [Abstract][Full Text] [Related]
4. Preclinical antitumor activity of bizelesin in mice. Carter CA; Waud WR; Li LH; DeKoning TF; McGovren JP; Plowman J Clin Cancer Res; 1996 Jul; 2(7):1143-9. PubMed ID: 9816280 [TBL] [Abstract][Full Text] [Related]
5. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta. Borden EC; Sidky YA; Hatcher JF; Bryan GT Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000 [TBL] [Abstract][Full Text] [Related]
6. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo. Elliott WL; Roberts BJ; Howard CT; Leopold WR Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790 [TBL] [Abstract][Full Text] [Related]
7. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice. Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799 [TBL] [Abstract][Full Text] [Related]
8. Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies. Rose WC J Natl Cancer Inst Monogr; 1993; (15):47-53. PubMed ID: 7912529 [TBL] [Abstract][Full Text] [Related]
9. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925 [TBL] [Abstract][Full Text] [Related]
10. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo. McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145 [TBL] [Abstract][Full Text] [Related]
11. Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin. Damia G; Tagliabue G; Zucchetti M; Davoli E; Sessa C; Cavalli F; D'Incalci M Cancer Chemother Pharmacol; 1992; 30(6):459-64. PubMed ID: 1394802 [TBL] [Abstract][Full Text] [Related]
12. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998 [TBL] [Abstract][Full Text] [Related]
13. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285 [TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine. Cao S; McGuire JJ; Rustum YM Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100 [TBL] [Abstract][Full Text] [Related]
15. Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide. Burres NS; Clement JJ Cancer Res; 1989 Jun; 49(11):2935-40. PubMed ID: 2720652 [TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts. Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476 [TBL] [Abstract][Full Text] [Related]
17. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines. Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778 [TBL] [Abstract][Full Text] [Related]
18. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo. Donnelly ET; Kelley M; Rockwell S Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460 [TBL] [Abstract][Full Text] [Related]
19. Antitumor, nephrotoxic and clastogenic effect of cis-DDP with DDTC or NAC. Konstantinov S; Topashka-Ancheva M; Karaivanova M; Zoneva G; Galova I Neoplasma; 1994; 41(5):253-8. PubMed ID: 7854494 [TBL] [Abstract][Full Text] [Related]